Fig 1: The transfection efficiency of T47D and MCF7 cells with miR-491-5p was determined by qRT-PCR (A). mRNA and protein expressions of VPS28 were detected by qRT-PCR (B) and Western blot (C). The predicted binding site of miR-491-5p and VPS28 3′UTR as determined by TargetScan (D). The binding of miR-491-5p to VPS28 was determined using the dual luciferase reporter assay (E). **p < 0.01, ***p < 0.01, n = 3.
Fig 2: The mRNA expression of VPS28 in pan-cancer cell lines and tissues. The mRNA expression pattern of VPS28 in pan-cancer cell lines according to data collected from the CCLE database (A) and in pan-cancer tissues from the TCGA database (B).
Fig 3: Micro RNA-491-5p inhibits the invasiveness and apoptosis of breast cancer cells by regulating VPS28. Cell invasiveness was measured using the transwell assay (A), while cell apoptosis was determined by flow cytometry (B). **p < 0.01, ***p < 0.001, n = 3.
Fig 4: VPS28 mRNA and protein expression levels in normal breast cell line and breast cancer cell lines. VPS28 mRNA and protein expression levels in MCF-10A and breast cancer cells (MDAMB231, BT474, MCF7, T47D, and MDAMB436) determined by qRT-PCR and Western blotting (A,B); * p < 0.05, **p < 0.01, n = 3.
Fig 5: VPS28 expression in different subtypes of breast cancer, according to the TCGA database (A). Batch multi-Cox regression analysis for OS showed that eight genes represented independent risk factors for breast cancer, including SLC6A9, ST14, PUF60, HSF1, NIPA2, VPS28, OPLAH, and SPON2 (B). K-M analysis shows that high expression VPS28 was associated with a poor prognosis of breast cancer patients (C). VPS28 protein expression levels in breast cancer tissues and normal mammary tissues according to the CPTAC database (D).
Supplier Page from Abcam for Anti-VPS28 antibody [EPR9880]